Published Paper Details:

COVID-19 is an infectious disease caused by a newly discovered coronavirus. The novel Corona virus, officially known as SARS COV-2 or coronavirus disease 2019 (COVID-19), was first reported in December 2019 as a cluster of acute respiratory illness in Wuhan, China from where it spread rapidly to over 198 countries. Vaccines have been a key strategy for improving health outcomes and life expectancy by controlling and preventing infectious diseases. The development of a safe and effective COVID-19 vaccine is a critical step to halt the pandemic. The aim of this study was to assess the prevalence of COVID infection among the vaccinated people in a selected community of New Delhi. The research approach was quantitative and descriptive research design was used. The sample selected was vaccinated people from a selected community of New Delhi. Structured Questionnaire Interview was developed to collect the data, which showed the prevalence was more in males than females who were in the age group of 21-35 years and after first dose of covishield. COVID-19 is an infectious disease caused by a newly discovered coronavirus. The novel Corona virus, officially known as SARS COV-2 or coronavirus disease 2019 (COVID-19), was first reported in December 2019 as a cluster of acute respiratory illness in Wuhan, China from where it spread rapidly to over 198 countries. Vaccines have been a key strategy for improving health outcomes and life expectancy by controlling and preventing infectious diseases. The development of a safe and effective COVID-19 vaccine is a critical step to halt the pandemic. The aim of this study was to assess the prevalence of COVID infection among the vaccinated people in a selected community of New Delhi. The research approach was quantitative and descriptive research design was used. The sample selected was vaccinated people from a selected community of New Delhi. Structured Questionnaire Interview was developed to collect the data, which showed the prevalence was more in males than females who were in the age group of 21-35 years and after first dose of covishield.